Axsome settles patent litigation with Teva

Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA related to patents for the psychiatry drug,
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.
Axsome stock target raised to $190 on Teva litigation resolution
TD Cowen adjusted its outlook on Axsome Therapeutics (NASDAQ:AXSM), a $6.16 billion market cap company, by increasing the price target to $190 from the previous $155, while maintaining a Buy rating on the company's shares.
Axsome secures top drug’s future with Teva patent settlement
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.
Axsome settles Auvelity patent litigation with Teva
Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a proposed generic version of Auvelity. Read more here.
Axsome Therapeutics stock rises on patent litigation settlement
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) surged 15% following the announcement of a settlement agreement with Teva Pharmaceuticals that resolves patent litigation over its flagship product, AUVELITY®.
Shares in Biopharma Firm Axsome Surge Over 20% After Settling Teva Patent Dispute
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
FiercePharma1d
Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
Why Axsome Therapeutics Stock Is Soaring Today
Shares of Axsome Therapeutics ( AXSM 4.07%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Why Axsome Therapeutics (AXSM) Is Advancing Today
Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...
Axsome Therapeutics price target raised to $195 from $137 at Mizuho
Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $195 from $137 and keeps an Outperform rating on the shares following ...
Why Axsome Therapeutics Stock Is Skyrocketing Today
Shares of Axsome Therapeutics ( AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m. ET, ...